Introduction

The United States is confronting a significant public health challenge as the drug‑resistant fungus Candida auris continues to spread across health‑care facilities. Provisional data for the week ending 25 July 2026 show a total of 3,437 clinical cases reported in 27 states, underscoring the need for coordinated action.

Scope of the Outbreak

California accounts for the largest share with 873 cases, roughly one‑quarter of the national total. Texas (433 cases), Tennessee (283), Ohio (279), Georgia (193), Louisiana (179), Illinois (171), Arizona (171), Michigan (146), Virginia (132) and Pennsylvania (121) follow closely. All remaining states have reported fewer than 100 cases each. These numbers reflect clinical detections—specimens collected during routine medical care—not necessarily confirmed infections.

Transmission and High‑Risk Patients

Candida auris spreads readily through contaminated surfaces and medical equipment. Items such as bedrails, doorknobs, blood‑pressure cuffs and shared devices can harbor the yeast for weeks, allowing transmission from one patient to another. Both infected and colonized individuals—those who carry the fungus without symptoms—can deposit organisms onto these surfaces. Patients with severe underlying conditions, especially those using breathing tubes, feeding tubes, central lines or urinary catheters, are most vulnerable. Frequent or prolonged hospital stays further increase exposure risk, while healthy individuals are unlikely to become colonized.

Drug Resistance and Clinical Impact

The fungus is notorious for its resistance to multiple antifungal drug classes. Laboratory testing of over 8,000 isolates from 2022‑2023 found that 95 % were resistant to fluconazole, 15 % to amphotericin B, and 1 % to the echinocandins that are currently the preferred first‑line treatment. Some strains have become resistant to all three major classes, complicating therapy. Invasive infections, particularly bloodstream involvement, carry mortality rates ranging from 30 % to 72 %, though many affected patients already have serious illnesses that contribute to outcomes.

Public Health Actions and Future Directions

The Centers for Disease Control and Prevention (CDC) has classified Candida auris as an urgent antimicrobial‑resistance threat. Hospitals are responding with a suite of preventive measures: rigorous hand hygiene, aggressive patient screening on admission, proper use of antifungal agents, isolation precautions for colonized or infected patients, and thorough environmental disinfection using agents proven effective against the yeast. Ongoing research aims to develop new antifungal therapies and rapid diagnostic tools to identify resistant strains more quickly.

Conclusion

While the 2026 case total is slightly lower than the previous year, the persistent spread of Candida auris across 27 states highlights the importance of sustained vigilance. By reinforcing infection‑control practices, advancing treatment options, and supporting public‑health surveillance, the health‑care community can mitigate the impact of this formidable fungus and safeguard vulnerable patients.